Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | BRS3 | P32247 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128352 | 0.89 | LTB4R2 (0.50) | PPARGBRS3CDK4CCND1LTB4R2 | |
| SCHEMBL28440024 | 0.81 | RORB (0.48) | BRS3CDK4CCND1LTB4R2RORB | |
| SCHEMBL23353984 | 0.77 | TACR1 (0.48) | BRS3LTB4R2HNF4A | |
| SCHEMBL29979035 | 0.77 | TACR1 (0.48) | BRS3LTB4R2HNF4A | |
| SCHEMBL6480249 | 0.77 | TRPV1 (0.53) | CDK4CCND1RORBNR1H4 | |
| SCHEMBL29971478 | 0.76 | CDK4 (0.52) | CDK4CCND1RORBNR1H4 | |
| SCHEMBL20504191 | 0.76 | NR1H4 (0.52) | PPARGRORBNR1H4AKR1C2AKR1C1 | |
| SCHEMBL294262 | 0.76 | HNF4A (0.67) | PPARGRORBNR1H4AKR1C2AKR1C1 | |
| SCHEMBL14102364 | 0.76 | CDK4 (0.52) | CDK4CCND1RORBNR1H4 | |
| SCHEMBL18759613 | 0.76 | HNF4A (0.63) | LTB4R2HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | PPARG 316/4885BRS3 2990/4885CDK4 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.